Treprostinil is a synthetic prostacyclin prescribed for the treatment of pulmonary arterial hypertension. Treprostinil works as a vasodilator lowering the blood pressure in the pulmonary artery leading from heart to lungs and is known to improve the ability to exercise. Treprostinil can be administered through oral route (orenitram), through inhaler (Tyvaso), and through infusion (Remodulin).
R&D of new formulations of treprostinil is expected to offer lucrative growth opportunities for players in the treprostinil drugs market. For instance, in November 2020, the U.S. Food and Drug Administration issued a complete response letter for the New Drug Application of Liquidia Technologies, Inc., a wholly owned subsidiary of Liquidia Corporation, for LIQ861 (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension.
Global Treprostinil Drugs Market – Competitive landscape
Key players operating in treprostinil drugs market are United Therapeutics, Novartis, and Teva Pharmaceutical Industries Ltd. Players in the market are focused on developing new products, in order to enhance their market share.
Read More: https://www.blogger.com/blog/post/preview/8474931090123965692/2306110042788675805
0
